Why Is IDEAYA BIOSCIENCES I (IDYA) Stock Down Today?
By the Top Tier Newswire AI Desk · November 18, 2026 at 12:09 AM ET · reviewed against 5 wire stories
IDEAYA BIOSCIENCES I (IDYA) is down -9.75% in the latest session. Our newswire has captured 5 stories on IDYA across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Ideaya Biosciences (IDYA) shares fell 9.75% to $27.40. The primary driver of the decline was the company’s announcement of its registrational trial strategy for IDE849, a potential best-in-class DLL3 TOP1 antibody-drug conjugate for neuroendocrine carcinomas.
What Happened
Ideaya Biosciences announced the successful conclusion of a US FDA Type C meeting regarding the Phase 2/3 registrational trial designs for IDE849. The company plans a single-arm extension cohort of approximately 90 refractory gastroenteropancreatic neuroendocrine carcinoma patients to support potential accelerated approval, with the objective response rate by blinded independent central review as the primary endpoint. Additionally, the firm outlined a randomized Phase 3 trial in multiple refractory neuroendocrine carcinoma subtypes. The company also nominated IDE101 as a development candidate for CDKN2A-deficient solid tumors.
What The Data Shows
The stock’s 52-week range is $26.81 to $42.68, and the company printed 28 fresh 52-week lows on November 17, 2026. Ideaya Biosciences has a market capitalization of $3.1 billion and remains unprofitable, with trailing twelve-month earnings per share of -4.52 and revenue down 83.0% over the same period. The stock has a beta of 0.08. In the last 90 days, there were zero insider buys and one sell totaling $985,000, with the most recent transaction on October 8, 2026. CEO Hata Yujiro S sold shares on October 6, 2026. Analysts have recently adjusted their views, with Wedbush adjusting its price target to $63 from $60 and RBC Capital Markets lowering its price target to $45.
What To Watch
Investors will monitor the upcoming November 2026 investor relations events where the company is scheduled to participate.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
IDYA · Nov 18 session (5-min) · -3.32% vs prior close · updated 8:53 PM ETAI sentiment, last 36h · averaged over 5 stories · 56/100 bullish
The headlines behind the move
Story flow · 5 stories on the wire, last 36h · hover or tap a dot for the headline
2d agoSeeking AlphaBULLISH 67Analyst
Ideaya Biosciences: Staying Bullish On Darovasertib NDA Submission And More
Ideaya Biosciences is continuing to advance its first-in-class, oral, small-molecule protein kinase C [PKC] inhibitor darovasertib. I rate IDYA stock as Strong Buy.
3d agoThe FlyBEARISH 31General
Ideaya Biosciences falls -11.8%
3d agoSeeking AlphaBULLISH 58Product/PR
Ideaya sets registrational trial strategy for IDE849 for neuroendocrine carcinomas
Ideaya plans a 90-patient IDE849 extension cohort in GEP-NEC to support accelerated approval, with confirmed response rate as the primary endpoint. Read more here.
3d agoThe FlyBULLISH 58Product/PR
Ideaya Biosciences reports on FDA Type C meeting on Phase 2/3 trial for IDE849
3d agoPR NewswireBULLISH 64Product/PR
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
Single-arm extension cohort of approximately 90 refractory GEP-NEC patients to support potential accelerated approval, with ORR by BICR as the primary endpoint Randomized Phase 3 trial in multiple refractory NEC subtypes, including GEP-NEC and LC-NEC, is planned to support full approval,...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →